In the original publication [1], we used the same blot in two figures (Figures 1D and 3C), but the accompanying figure legend does not match. We wish to include a few lines in the existing legend. The correct legend appears below:
Figure 3. Synergistic effect of DNA-PK inhibitor KU-0060648 with THZ531: (A) MTT assay to predict synergistic growth inhibition of KMS18, KMS28, and RPMI-8226 MM cells in the presence of THZ531 and DNA-PK inhibitor KU-0060648. (B) Synergy and CI prediction of combination treatment. The combination index (CI) defines interaction between THZ531 and KU-0060648 plotted as a fraction of cell viability. CI < 1, CI = 1, and CI > 1 represent synergism, additive effects, and antagonism, respectively, of the two compounds. (C) Immunoblotting for cleaved Caspase-9 and cleaved PARP in KMS18, KMS28, and RPMI-8226 treated with increasing doses of THZ531 (0, 50, 100, 250 nM) alone or in combination with 0.5 µM KU-0060648. GAPDH and H3 were used as loading control. The THZ531 PARP blot shown in Figure 3C (KMS18 and RPMI-8226) was derived from the same experiment as that in Figure 1D, reused here to demonstrate the KU-combination condition.
There was also a mistake in the original publication [1]: a correction has been made to Figure 1B. After re-examining the original image files, we confirmed that an inadvertent mix-up occurred during figure assembly. Specifically, the RNA Pol II Ser2 and RNA Pol II panels for KMS18 and KMS28 were incorrectly interchanged. A revised Figure 1B has been generated directly from these raw blots. We sincerely apologize for this unintentional oversight. The correct Figure 1 appears below.
Figure 1.
Multiple myeloma cells are highly sensitive to THZ531. (A) A diverse panel of multiple myeloma cells lines were treated with either DMSO (control) or increasing concentrations of THZ531. Cell viability was assessed 72 h following treatment. (B) Western blot depicting the effect of THZ531 on p-RNA Pol II Ser 2 in2 myeloma cell lines. Alpha tubulin was the loading control. (C) Effect of increasing concentration of THZ 531 on the percentage of Annexin V+ cells measured via flow cytometry at 24 h. (D) Western blot depicting the effect of THZ 531 on PARP cleavage at 24 h. Beta-actin was used as the loading control. (E) Effect of THZ531 on 3 multiple myeloma patient samples (CD138+). Samples were treated with THZ531 for 48 h, and viability was measured using Cell titre glo assay. Data for (C,E) are presented as the mean ± SD of the mean. Statistical analysis was carried out using GraphPad Prism software, version 7 (GraphPad, La Jolla, CA, USA). Statistical significance was determined using an unpaired Student’s t-test or ANOVA followed by Tukey’s post hoc test. ns—not significant; p < 0.05 considered significant. *** p < 0.0002, **** p < 0.0001.
The authors state that the scientific conclusions are unaffected. These corrections were approved by the Academic Editor. The original publication has also been updated.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Reference
- 1.Shyamsunder P., Sridharan S.P., Madan V., Dakle P., Zeya C., Kanojia D., Chng W.-J., Ong S.T., Koeffler H.P. THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. Int. J. Mol. Sci. 2022;23:1207. doi: 10.3390/ijms23031207. [DOI] [PMC free article] [PubMed] [Google Scholar]